Document Detail


Vigabatrin for refractory complex partial seizures: multicenter single-blind study with long-term follow-up.
MedLine Citation:
PMID:  3808298     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The irreversible GABA transaminase inhibitor vigabatrin (VGB) was given in a single-blind fashion to 89 patients with complex partial seizures (CPS) refractory to conventional drugs. The median number of CPS per month decreased from 11.0 to 5.0 after addition of VGB, and 51% of patients had a 50% or greater decrease in CPS frequency (p less than 0.001). Side effects (principally drowsiness, ataxia, and headache) occurred mainly during the initiation of therapy and decreased during therapy. After 12 weeks on VGB, side effects significantly interfered with functioning in only 13% of patients, and the efficacy:toxicity ratio warranted continued administration in 74% of patients. Coadministration of VGB resulted in a mean decrease of 20% in phenytoin serum concentration (p less than 0.001). Sixty-six patients with a favorable response to VGB during the single-blind study have been followed for a median of 16.7 months on VGB. No serious systemic or neurologic toxicity has been detected, and most patients have retained their initial favorable CPS control.
Authors:
T R Browne; R H Mattson; J K Penry; D B Smith; D M Treiman; B J Wilder; E Ben-Menachem; M J Napoliello; K M Sherry; G K Szabo
Related Documents :
1963498 - The relationship between response to fluoxetine, plasma drug levels, imipramine binding...
15907758 - "seizure-alert dogs": observations from an inpatient video/eeg unit.
8795128 - An audit of the new antiepileptic drugs in clinical neurological practice.
7007988 - Is the therapy with carbamazepine more effective when measuring blood levels?
7445538 - The significance of electron dense deposits in mild lupus nephritis.
807098 - Bone marrow histology in monoclonal macroglobulinemia.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neurology     Volume:  37     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1987 Feb 
Date Detail:
Created Date:  1987-03-10     Completed Date:  1987-03-10     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  184-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aminocaproic Acids / adverse effects,  metabolism,  therapeutic use*
Anticonvulsants / adverse effects,  metabolism,  therapeutic use*
Drug Interactions
Epilepsy, Temporal Lobe / drug therapy*
Follow-Up Studies
Humans
Vigabatrin
Chemical
Reg. No./Substance:
0/Aminocaproic Acids; 0/Anticonvulsants; 60643-86-9/Vigabatrin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Early diagnosis of herpes simplex encephalitis by MRI.
Next Document:  Lorazepam in childhood status epilepticus and serial seizures: effectiveness and tachyphylaxis.